Shares of Aurobindo Pharma were trading higher in early trade on April 15, 2025, after the company received final approval from the US Food and Drug Administration (USFDA) for its Rivaroxaban tablets, a generic version of Xarelto used to prevent and treat blood clots. The approved drug has a market size of approximately 8.5 billion US dollars in the United States.
As of 9:22 AM IST, Aurobindo Pharma was trading at Rs 1,108.30, up 2.39 percent or Rs 25.85 from its previous close of Rs 1,082.45. The stock opened at Rs 1,110.00 and touched a high of Rs 1,116.20 and a low of Rs 1,099.00 during early trade. The average trading price stood at Rs 1,107.31 with volumes of over 1.22 lakh shares and open interest at 2.93 crore shares.
The drug is part of Aurobindo’s ongoing effort to expand its portfolio of complex generics, and the approval is expected to strengthen the company’s position in the U.S. market, especially in the high-value anticoagulant segment.
The company’s 52-week range spans between Rs 1,010.00 and Rs 1,592.00, with the upper circuit limit currently at Rs 1,190.70.
Disclaimer: The above information is based on stock exchange data and publicly available regulatory updates as of 9:22 AM IST on April 15, 2025. Please consult a financial advisor before making any investment decisions.
